Article

Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted<i>TP53</i>

2024-12-02

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Patients with relapsed/refractory multiple myeloma (RRMM) and high-risk genetic abnormalities such as del(17p) and TP53 mutation have poor response to standard therapies and shorter survival compared to patients without these aberrations. Here, we investigated the activity and mechanism of action of peptide-drug conjugate melphalan flufenamide (melflufen) in TP53 wild type ( T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9212c8c9-a447-55bf-b299-9c1411c9d9f8
DOI: 10.1101/2024.12.02.24318289

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted<i>TP53</i>DOI 10.1101/2024.12.02.24318289Read

Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myelomaSemantic proximity Read

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read

Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma ModelsSemantic proximity Read

Deregulation and Targeting of TP53 Pathway in Multiple MyelomaSemantic proximity Read

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple MyelomaSemantic proximity Read

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cellsSemantic proximity Read

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.Semantic proximity Read

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survivalSemantic proximity Read

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.Semantic proximity Read

Functional transcriptomic landscape informs novel therapeutic strategies in multiple myelomaSemantic proximity Read

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaSemantic proximity Read

Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells <i>In Vivo</i>Semantic proximity Read